KR920700636A - 인체의 악성 종양을 치료하기 위한 1,2-벤조피론 유도체의 용도 - Google Patents

인체의 악성 종양을 치료하기 위한 1,2-벤조피론 유도체의 용도

Info

Publication number
KR920700636A
KR920700636A KR1019910700768A KR910700768A KR920700636A KR 920700636 A KR920700636 A KR 920700636A KR 1019910700768 A KR1019910700768 A KR 1019910700768A KR 910700768 A KR910700768 A KR 910700768A KR 920700636 A KR920700636 A KR 920700636A
Authority
KR
South Korea
Prior art keywords
benzopyrone
human body
drug
producing
malignant tumors
Prior art date
Application number
KR1019910700768A
Other languages
English (en)
Other versions
KR0177821B1 (en
Inventor
R. 도우글라스 토로네스
헬가 스톨제
어니스트 마샬
크루트 젠커
Original Assignee
원본미기재
샤퍼 운트 브류머 게엠바하 운트 코
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 샤퍼 운트 브류머 게엠바하 운트 코 filed Critical 원본미기재
Publication of KR920700636A publication Critical patent/KR920700636A/ko
Application granted granted Critical
Publication of KR0177821B1 publication Critical patent/KR0177821B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Monitoring And Testing Of Nuclear Reactors (AREA)
  • External Artificial Organs (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

내용 없음

Description

인체의 악성종양을 치료하기 위한 1,2-벤조피론 유도체의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. 인체의 악성종양의 예방적 치료 및/또는 치료적 처치용 약물을 생산하기 위한 7-OH-1,2-벤조피론의 용도.
  2. 제1항에 있어서, 일반적인 세포증식 억제제와 혼합된 7-OH-1,2-벤조피론의 용도.
  3. 제1항에 있어서, 사이토킨과 혼합된 7-OH-1,2-벤조피론의 용도.
  4. 제1내지 3항에 있어서, 인체의 악성 종양의 예방적 치료를 위해 50내지 300㎎의 1일 용량으로 사용되는 7-OH-1,2-벤조피론의 용도.
  5. 제1내지 3항에 있어서, 인체의 악성 종양의 치료적 처치를 위해 300내지 6000㎎의 1일 용량으로 사용되는 7-OH-1,2-벤조피론의 용도.
  6. 제1내지 5항에 있어서, 뇌종양 치료용 약물을 생산하기 위한 7-OH-1,2-벤조피론의 용도.
  7. 제1내지 5항에 있어서, 인체의 신장암, 전립선암, 피부암, 폐암 또는 백혈병 치료용 약물을 생산하기 위한 7-OH-1,2-벤조피론의 용도.
  8. 제1내지 5항에 있어서, 종양원 바현에 의해 유발된 종양의 치료용 약물을 생산하기 위한 7-OH-1,2-벤조피론의 용도.
  9. 제1항에 있어서, 호르몬-의존성 종양 치료용 약물을 생산하기 위한 것으로서 호르몬과 혼합된 7-OH-1,2-벤조피론의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910700768A 1989-11-24 1991-07-22 Pharmaceutical compositions containing 1,2-benzopyrone derivatives for the treatment of malignant tumours in humans KR0177821B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP3938902.2 1989-11-24
DE3938902A DE3938902C1 (ko) 1989-11-24 1989-11-24

Publications (2)

Publication Number Publication Date
KR920700636A true KR920700636A (ko) 1992-08-10
KR0177821B1 KR0177821B1 (en) 1999-03-20

Family

ID=6394102

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910700768A KR0177821B1 (en) 1989-11-24 1991-07-22 Pharmaceutical compositions containing 1,2-benzopyrone derivatives for the treatment of malignant tumours in humans

Country Status (11)

Country Link
EP (1) EP0455769B1 (ko)
JP (1) JP3053645B2 (ko)
KR (1) KR0177821B1 (ko)
AT (1) ATE128354T1 (ko)
AU (1) AU6739690A (ko)
BR (1) BR9007080A (ko)
CA (1) CA2045593C (ko)
DE (2) DE3938902C1 (ko)
DK (1) DK0455769T3 (ko)
FI (1) FI913531A0 (ko)
WO (1) WO1991007959A1 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2822379B1 (fr) * 2001-03-20 2007-06-15 Sederma Sa Compositions cosmetiques et dermopharmaceutiques contenant de l'umbelliferone
US7148252B2 (en) * 2001-10-03 2006-12-12 Signal Pharmaceuticals, Llc Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985003865A1 (en) * 1984-03-01 1985-09-12 Casley Smith John Royle Treatment of high protein oedemas in animals

Also Published As

Publication number Publication date
FI913531A0 (fi) 1991-07-23
JPH04505020A (ja) 1992-09-03
CA2045593A1 (en) 1991-05-25
KR0177821B1 (en) 1999-03-20
ATE128354T1 (de) 1995-10-15
WO1991007959A1 (de) 1991-06-13
AU6739690A (en) 1991-06-26
CA2045593C (en) 2000-09-05
JP3053645B2 (ja) 2000-06-19
DK0455769T3 (da) 1996-02-05
EP0455769B1 (de) 1995-09-27
EP0455769A1 (de) 1991-11-13
BR9007080A (pt) 1991-12-24
DE3938902C1 (ko) 1991-05-08
DE59009724D1 (de) 1995-11-02

Similar Documents

Publication Publication Date Title
CY1105818T1 (el) Χρησεις του et743 στην θepαπευτικη αγωγη του καρκινου
TR200003879T2 (tr) İn vivo ışın tedavisine duyarlılaştırıcı özelliklere sahip farnesil protein transferaz inhibitörleri@
NZ285159A (en) Treatment of benign prostatic hyperplasia, endometriosis, prostatic carcinoma and obesity by administration of droloxifene
DE3481893D1 (de) Hyperthermie-apparat.
ATE241375T1 (de) Verwendung eines serenoa repens extraktes zur herstellung eines arzneimittels zur behandlung von krebserkrankungen der prostata
ES2147780T3 (es) Compuestos sinteticos afines al extracto de corteza de roble, y procedimiento para utilizar los mismos.
PT933995E (pt) Metodo para tratamento de lesao endotelial
ES444494A1 (es) Procedimiento para la preparacion de antracicliononas opti- camente activas.
HRP20080598T3 (en) Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer
BR0115162A (pt) Tratamentos antitumorais eficazes
HUP9900905A2 (hu) D4-Vitamin származékok alkalmazása rák kezelésére szolgáló gyógyászati készítmények előállítására
ES2097905T3 (es) Agentes terapeuticos para el tratamiento de la resistencia multidroga de canceres.
NZ504928A (en) Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
DK0841912T3 (da) 2-Aminocarbonyl-1,2-bis-(methylsulfonyl)-1-(substituerede)-hydraziner med antitumor-virkning
KR920700636A (ko) 인체의 악성 종양을 치료하기 위한 1,2-벤조피론 유도체의 용도
MX2024003563A (es) Composicion farmaceutica combinada de inhibidor de cdk4/6 e inhibidor de aromatasa.
MX2023009962A (es) Composicion farmaceutica combinada que contiene inhibidor de cdk4/6 y su uso.
AU1703195A (en) Verotoxin pharmaceutical compositions and medical treatments therewith
ES2058161T3 (es) Producto activo para la lucha contra tumores.
WO2000004153A3 (en) Repression of cell transformation with human pea3
ES2162092T3 (es) Terapia de combinacion para canceres avanzados que comprende temozolomida y cisplatino.
DK1003559T3 (da) Immobilisering af vitamin A-syre ved kationiske polyelektrolytter
ES2019713A6 (es) Un procedimiento para preparar derivados clorados de adenosina.
DE59908268D1 (de) Khellin-zubereitung und deren verwendung zur topischen therapie
RU2233662C1 (ru) Способ профилактики местных лучевых реакций

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
N231 Notification of change of applicant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20071107

Year of fee payment: 10

LAPS Lapse due to unpaid annual fee